Angelica Linnea Quartino1, Lena E Friberg, Mats O Karlsson. 1. The Pharmacometrics Research Group, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-751 24 Uppsala, Sweden. angelica.quartino@farmbio.uu.se
Abstract
PURPOSE: To improve the predictive capacity of a semi-mechanistic myelosuppression model for neutrophils as the model have shown to over-predict the nadir of neutrophils and, secondly, to develop a model describing the time-course of leukocytes and neutrophils simultaneously. EXPERIMENTAL DESIGN: The study included 601 cancer patients treated with a 1 h infusion of docetaxel in monotherapy. A total of 3,549 pairwise observations of leukocytes and neutrophils from one treatment cycle were analyzed simultaneously in NONMEM. RESULTS: A basic model was developed consisting of a neutrophil and a non-neutrophil model, each with the same structure as the semi-mechanistic myelosuppression model. The leukocytes were modeled as the sum of the predicted neutrophils and non-neutrophils. The model described the time-course of the leukocytes well, but was not able to capture the nadir of the neutrophils. Hence the model was further refined and the included modifications (p < 0.001) in the final model are a sigmoid Emax functions for the drug effect, feedback functions on the cell maturation time in bone-marrow and an optimized number of transit compartments for each of the two cell types. CONCLUSIONS: A joint semi-mechanistic myelosuppression model describing the time-course of leukocytes and neutrophils following docetaxel administration was developed. The data supported a more complex model compared to the previous model developed by Friberg et al. (2002), and increased the model's capacity to accurately describe the time-course of neutrophils following docetaxel therapy. The combined model also illustrates the differences between the cell types and allows prediction of neutrophil counts from leukocyte measurements.
PURPOSE: To improve the predictive capacity of a semi-mechanistic myelosuppression model for neutrophils as the model have shown to over-predict the nadir of neutrophils and, secondly, to develop a model describing the time-course of leukocytes and neutrophils simultaneously. EXPERIMENTAL DESIGN: The study included 601 cancerpatients treated with a 1 h infusion of docetaxel in monotherapy. A total of 3,549 pairwise observations of leukocytes and neutrophils from one treatment cycle were analyzed simultaneously in NONMEM. RESULTS: A basic model was developed consisting of a neutrophil and a non-neutrophil model, each with the same structure as the semi-mechanistic myelosuppression model. The leukocytes were modeled as the sum of the predicted neutrophils and non-neutrophils. The model described the time-course of the leukocytes well, but was not able to capture the nadir of the neutrophils. Hence the model was further refined and the included modifications (p < 0.001) in the final model are a sigmoid Emax functions for the drug effect, feedback functions on the cell maturation time in bone-marrow and an optimized number of transit compartments for each of the two cell types. CONCLUSIONS: A joint semi-mechanistic myelosuppression model describing the time-course of leukocytes and neutrophils following docetaxel administration was developed. The data supported a more complex model compared to the previous model developed by Friberg et al. (2002), and increased the model's capacity to accurately describe the time-course of neutrophils following docetaxel therapy. The combined model also illustrates the differences between the cell types and allows prediction of neutrophil counts from leukocyte measurements.
Authors: A S Zandvliet; W S Siegel-Lakhai; J H Beijnen; W Copalu; M-C Etienne-Grimaldi; G Milano; J H M Schellens; A D R Huitema Journal: Clin Pharmacol Ther Date: 2007-09-12 Impact factor: 6.875
Authors: Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri H Roché; Jean-Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens Journal: Invest New Drugs Date: 2005-06 Impact factor: 3.850
Authors: R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Cristina Segura; Eva Bandrés; Iñaki F Trocóniz; Jesús García-Foncillas; Onintza Sayar; Carmen Dios-Vieítez; Maria Jesús Renedo; María J Garrido Journal: Pharm Res Date: 2004-04 Impact factor: 4.200
Authors: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens Journal: Clin Pharmacokinet Date: 2007 Impact factor: 6.447
Authors: Emma K Hansson; Johan E Wallin; Henrik Lindman; Marie Sandström; Mats O Karlsson; Lena E Friberg Journal: Cancer Chemother Pharmacol Date: 2009-08-14 Impact factor: 3.333
Authors: Mario González-Sales; Belén Valenzuela; Carlos Pérez-Ruixo; Carlos Fernández Teruel; Bernardo Miguel-Lillo; Arturo Soto-Matos; Juan Jose Pérez-Ruixo Journal: Clin Pharmacokinet Date: 2012-11 Impact factor: 6.447
Authors: Daniel Câmara De Souza; Morgan Craig; Tyler Cassidy; Jun Li; Fahima Nekka; Jacques Bélair; Antony R Humphries Journal: J Pharmacokinet Pharmacodyn Date: 2017-12-13 Impact factor: 2.745
Authors: Murad Melhem; Isabelle Delor; Juan Jose Pérez-Ruixo; John Harrold; Andrew Chow; Liviawati Wu; Philippe Jacqmin Journal: Br J Clin Pharmacol Date: 2018-02-20 Impact factor: 4.335
Authors: Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo Journal: Clin Pharmacokinet Date: 2013-12 Impact factor: 6.447